Stock Movers: CPRI, APGE, ZS (Podcast)

Capri Holdings rose after fourth-quarter adjusted EPS beat analyst estimates, while Zscaler fell on a weaker-than-expected Q4 revenue outlook and Evercore downgrade citing slowing net new customers. Apogee Therapeutics also traded lower after trial results, despite announcing a financing collaboration with Blackstone Life Sciences. The article is a stock-movers update centered on mixed earnings, guidance, and trial/news-driven reactions.

Analysis

The dispersion here is more informative than the individual moves: the market is rewarding near-term earnings power where it can be underwritten from existing demand, while punishing any sign that forward growth is decelerating or trial risk is re-asserting itself. ZS is the cleanest read-through for the cybersecurity complex because the issue is not absolute growth, but the rate of customer acquisition and forward bookings visibility; that typically compresses multiples faster than a modest EPS miss. If the slowdown is real rather than a one-quarter digestion effect, it will likely pressure the higher-duration software names first and then bleed into peers with similar net-new-logo exposure.

For APGE, the financing collaboration partially de-risks the balance sheet, but it does not erase binary clinical risk. In biotech, a capital solution can ironically shorten the stock’s fuse if it keeps burn funded without materially improving probability-adjusted pipeline value; that sets up a wider gap between financing support and fundamental rerating. Over the next 1-3 months, the key question is whether investors treat the trial data as a program-specific setback or a signal that platform expectations need to be haircut across adjacent immunology names.

CPRI’s move is more nuanced than a simple earnings beat: in consumer/luxury, any quarter that clears estimates can force short covering, but the durability of the move depends on whether gross margin improvement is coming from mix, inventory normalization, or genuine pricing power. The second-order implication is that suppliers and mall-exposed peers can see sympathy bids only if the market starts extrapolating an inflection in discretionary demand; otherwise this is a tactical squeeze, not a new cycle. The contrarian read is that the strongest reaction may be in the weakest consensus names, where even modest stabilization can drive outsized multiple expansion over the next 6-8 weeks.

Key Decisions for Investors

• Short ZS on any post-print bounce for a 2-6 week horizon; risk/reward favors lower multiples if the market starts pricing a slower net-new customer trajectory, with downside amplified if peers confirm similar demand friction.
• Pair trade: long a profitable, more resilient cybersecurity platform and short ZS as a relative-value expression; use this if you want sector exposure without paying for decelerating growth duration.
• Avoid chasing APGE strength from the financing headline; if the tape stabilizes, use it to reduce exposure or buy put spreads into the next catalyst, since clinical downside can reprice quickly while financing support only reduces liquidity risk.
• Trade CPRI tactically only: consider a short-dated call spread or small long into follow-through if the market is still underpositioned, but take profits quickly unless management commentary confirms the beat was driven by durable margin improvement.